Nanoform Finland Plc represents a strong set of values and a robust corporate philosophy. As a company, Nanoform is committed to delivering groundbreaking nanoparticle medicines to enhance the lives of patients worldwide. They prioritize innovation, scientific excellence, and collaboration in their pursuit of developing and commercializing novel drug candidates with their proprietary CESS® technology. Nanoform also emphasizes sustainability, taking responsibility for their environmental impact and fostering ethical business practices. Through their dedication to improving healthcare and their focus on sustainable growth, Nanoform Finland Plc aims to create long-term value for all its stakeholders.

Nanoform Finland Plc is primarily present in Finland, where its headquarters are located. As a Finnish nanotechnology company, Nanoform focuses on providing nanonization and nanoformulation services to pharmaceutical companies globally. While its presence is primarily concentrated in Finland, Nanoform serves clients from various countries and regions worldwide, collaborating with pharmaceutical companies to enhance drug solubility and bioavailability. Additionally, Nanoform strives to expand its presence to other global markets to offer its advanced nanonization technology and improve drug development processes internationally.

Nanoform Finland Plc has achieved several significant milestones. Firstly, the company successfully listed on the Nasdaq First North Premier Growth Market in 2020, allowing increased visibility and access to capital. Additionally, Nanoform expanded its business operations internationally by establishing a subsidiary in the United States and signing partnership agreements with prominent pharmaceutical companies. The company also received multiple grants and funds to support its research and development activities. Furthermore, Nanoform advanced its proprietary Controlled Expansion of Supercritical Solutions (CESS) technology, enabling the creation of nanoformed drug particles with enhanced drug properties. These achievements demonstrate Nanoform Finland Plc's commitment to innovation and market leadership in the field of nanomedicine.

Nanoform Finland Plc is a Finnish pharmaceutical company specializing in nanotechnology-enabled drug delivery solutions. Founded in 2005, Nanoform focuses on transforming poorly soluble drugs into more effective and accessible medications. The company's innovative nanotechnology platform, known as CESS® (Continuous Expansion of Supercritical Solutions), enhances drug solubility and bioavailability. By utilizing this platform, Nanoform collaborates with leading global pharmaceutical companies to develop novel therapeutics and effectively address unmet medical needs. With its cutting-edge technology and expertise, Nanoform is poised to revolutionize drug development and improve patient outcomes.

The main competitors of Nanoform Finland Plc in the market include other companies operating in the field of pharmaceutical drug delivery solutions. These competitors strive to provide innovative and efficient drug formulation technologies, similar to Nanoform Finland Plc. Some notable competitors in this space include Capsugel (now Lonza), Catalent Pharma Solutions, and Particle Sciences. These companies compete with Nanoform Finland Plc by offering their own range of services and technologies aimed at enhancing drug solubility, bioavailability, and overall therapy efficacy. Nanoform Finland Plc, however, differentiates itself through its unique nanoparticle engineering platform, offering potential advantages in terms of drug optimization and delivery.

Nanoform Finland Plc is primarily active in the pharmaceutical and healthcare industries.

Nanoform Finland Plc operates on an innovative business model, specializing in nanotechnology-enabled drug particle engineering. The company provides cutting-edge solutions to the pharmaceutical industry, aimed at improving the solubility and bioavailability of drug compounds. Nanoform utilizes its proprietary technology known as Controlled Expansion of Supercritical Solutions (CESS®) to enable the production of nano-sized drug particles. These nanoparticles can enhance drug performance and enable their successful formulation and delivery. By collaborating with pharmaceutical companies, Nanoform aims to facilitate the development of more effective and efficient medications. Their expertise in nanotechnology makes Nanoform Finland Plc a valuable player in the pharmaceutical industry.

De Nanoform Finland Oyj K/W is -4,31.

De Nanoform Finland Oyj KUV is 18,99.

De AlleAktien Kwaliteitsscore voor Nanoform Finland Oyj is 3/10.

De verwachte Nanoform Finland Oyj omzet is 4,80 mln. EUR.

De verwachte Nanoform Finland Oyj winst is -21,16 mln. EUR.

Nanoform Finland Plc is an innovative pharmaceutical company focused on the development of drugs. The company is based in Helsinki, Finland, and is known for its exceptional technology platform called CESS® (Continuous Expanded Sampling Spray). The platform can be used in the production of medical active substances to improve their effectiveness and bioavailability. One common disadvantage of many active substances in the pharmaceutical industry is their poor solubility in water, making it difficult for them to be absorbed by the body. However, Nanoform provides a solution to this problem. The company reduces the size of the active substance to a microscopic level, giving it a larger surface area so that it can be more easily absorbed by cells. Nanoscale drugs not only provide higher availability and effectiveness, but also better tolerability with a relatively low consumption of active substances. This makes Nanoform's concept more cost-effective than conventional drugs. Nanoform's products include a variety of drugs produced using CESS. These include prescription and over-the-counter products used to treat diseases such as cancer, diabetes, inflammation, and pain. In the "Prescription Products" division, Nanoform develops drugs in collaboration with leading pharmaceutical companies. Nanotransformation helps these drugs to be more effective and better tolerated. In addition to prescription drugs, Nanoform also produces drugs with a pure CBD formula, a sector that has become increasingly popular in recent times. These products are free from THC and therefore free from psychoactive effects. They can help relieve pain and inflammation, reduce anxiety, and improve sleep. Furthermore, Nanoform manufactures drugs for the treatment of rare diseases, also known as "orphan drugs". As these specialized drugs typically target a smaller market, the manufacturers often charge higher prices. Their high-quality products make an important contribution to improving and enhancing the health of millions of people worldwide. Nanoform has recently partnered with a British pharmaceutical company called Smerud Medical Research International to produce highest-quality micronized CBD formulas worldwide. Overall, Nanoform's business model focuses on advanced, cost-conscious, and innovative modification of drugs. The promise to improve the bioavailability of drugs based on the CESS technology platform has attracted a high number of partnerships, investors, and orders.

Nanoform Finland Oyj keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Nanoform Finland Oyj of het bedrijf keert geen dividend uit.

De ISIN van Nanoform Finland Oyj is FI4000330972.

Het WKN van Nanoform Finland Oyj is A2P5N7.

De ticker van Nanoform Finland Oyj is NANOFH.HE.

Binnen de laatste 12 maanden betaalde Nanoform Finland Oyj een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Nanoform Finland Oyj naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van Nanoform Finland Oyj is momenteel .

Nanoform Finland Oyj betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Nanoform Finland Oyj betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

Nanoform Finland Oyj wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Nanoform Finland Oyj van 9-11-2024 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 9-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 9-11-2024.

In het jaar 2023 heeft Nanoform Finland Oyj 0 EUR aan dividenden uitgekeerd.

De dividenden van Nanoform Finland Oyj worden in EUR uitgekeerd.